Regulatory14 Jul 2026, 12:13 pm
Sudarshan Pharma: Revised SEBI Takeover Disclosure for Share Pledge
AI Summary
Sudarshan Pharma Industries Ltd has submitted a revised disclosure under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, concerning share pledge by Hemal Vasantrai Mehta. The revision addresses queries raised by the exchange regarding discrepancies in post-event holding of encumbered shares, the reason for encumbrance, and adherence to the prescribed disclosure format. The company has rectified these issues, ensuring the disclosure now aligns with Regulation 31(2) and the updated SEBI circular format.
Key Highlights
- Revised SEBI takeover disclosure submitted for Hemal Vasantrai Mehta.
- Rectified discrepancies in encumbered shares holding post-event.
- Reason for pledge creation/release is now disclosed.
- Disclosure format updated as per SEBI circular requirements.
Price Impact
More from SUDARSHAN